Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Heidi Øyen Flemmen"'
Autor:
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, Kamilla Brekke, Cathrine Brunborg, Pål Berg-Hansen, Elisabeth Gulowsen Celius
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
IntroductionNo evidence of disease activity with three components (NEDA-3) is achieved if the person with MS (pwMS) has no new MRI lesions, no new relapses and no change in Expanded disability status scale (EDSS) over 1 year. Whether NEDA-3 is a good
Externí odkaz:
https://doaj.org/article/a8078941f0ce4f98a683c3c26b1228d4
Autor:
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, Cathrine Brunborg, Pål Berg-Hansen, Stine Marit Moen, Elisabeth Gulowsen Celius
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment guidelines only recommend high efficacy DMTs for patients with highly active MS. The objective was to examine
Externí odkaz:
https://doaj.org/article/2f09fb42838145d8bb7aab92ab8ece5e
Autor:
Randi Eikeland, Unn Ljøstad, Geir Helgeland, Geir Sand, Heidi Øyen Flemmen, Margrete Halvorsen Bø, Ludmila Nordaa, Jone Furulund Owe, Åse Mygland, Åslaug Rudjord Lorentzen
Publikováno v:
Brain and Behavior, Vol 10, Iss 4, Pp n/a-n/a (2020)
Abstract Objective To chart patient‐reported outcome measures (PROMs) in Norwegian patients treated for definite neuroborreliosis (NB). Material and Methods Adult patients treated for definite NB 1–10 years earlier supplied demographics, symptoms
Externí odkaz:
https://doaj.org/article/72850cb6d5bc477ca8877b5d2d959534
Autor:
Line Broch, Heidi Øyen Flemmen, Cecilia Smith Simonsen, Pål Berg-Hansen, Heidi Ormstad, Cathrine Brunborg, Elisabeth Gulowsen Celius
Publikováno v:
Multiple Sclerosis and Related Disorders
Objectives: Fatigue is one of the leading causes of reduced quality of life and inability to work in people with multiple sclerosis (pwMS). Currently, no treatment effectively ameliorates fatigue. We still know little about what causes fatigue and wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58a4314389d800b30309ff714f936162
https://hdl.handle.net/11250/3035644
https://hdl.handle.net/11250/3035644
Autor:
Cathrine Goberg Olsen, Øyvind Løvold Busk, Tori Navestad Aanjesen, Karl Bjørnar Alstadhaug, Ingrid Kristine Bjørnå, Geir Julius Braathen, Kristin Lif Breivik, Natasha Demic, Heidi Øyen Flemmen, Erika Hallerstig, Ineke HogenEsch, Øystein Lunde Holla, Anne Berit Jøntvedt, Margitta T. Kampman, Grethe Kleveland, Helene Ballo Kvernmo, Unn Ljøstad, Angelina Maniaol, Åse Hagen Morsund, Ola Nakken, Camilla Novy, Tiina Rekand, Katrin Schlüter, Stephan Schüler, Kristian Tveten, Ole-Bjørn Tysnes, Trygve Holmøy, Helle Høyer
Publikováno v:
Neuroepidemiology
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons. In Europe, disease-causing genetic variants have been identified in 40–70% of familial ALS patients and approximately 5% of sporadic ALS pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9014ee07cbbab9984c2aabf99aa3f7
http://hdl.handle.net/10852/95034
http://hdl.handle.net/10852/95034
Autor:
Anne Marit Solheim, Åslaug Rudjord Lorentzen, Audun Olav Dahlberg, Heidi Øyen Flemmen, Synne Brune, Kristine Johanne Nordstrøm Forselv, Are Hugo Pripp, Margrete Halvorsen Bø, Randi Eikeland, Harald Reiso, Åse Mygland, Unn Ljøstad
Publikováno v:
Journal of Neurology, Neurosurgery and Psychiatry
BackgroundThere is limited evidence regarding optimal duration of antibiotic treatment in neuroborreliosis. We aimed to compare efficacy and safety of oral doxycycline for 2 and 6 weeks in European Lyme neuroborreliosis (LNB).MethodsThe trial had a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e88f68ced156a2ec112205392d98af
https://hdl.handle.net/11250/3017836
https://hdl.handle.net/11250/3017836
Autor:
Heidi Øyen Flemmen, Elin Dahl, Håkon Tobro, Ottar Berg, Tormod Helås, Frøydis Dalene, Sarka Øygarden, Anne Jøntvedt
Publikováno v:
Tidsskrift for Den norske legeforening.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dcdb079640434638c428766992003c9
https://doi.org/10.4045/tidsskr.22.0143
https://doi.org/10.4045/tidsskr.22.0143
Autor:
Cecilie Fredvik Torkildsen, Åslaug R. Lorentzen, Cecilia Smith Simonsen, Karine Eid, Kjell-Morten Myhr, Marte-Helene Bjørk, Nils Erik Gilhus, Stig Wergeland, Trond Riise, Øivind Torkildsen, Nina Øksendal, Jan Harald Aarseth, Trygve Holmøy, Heidi Øyen Flemmen, Johannes Sverre Willumsen
Publikováno v:
Neurology
e2789-e2800
e2789-e2800
ObjectiveTo assess the occurrence of perinatal depression and anxiety in women before and after diagnosis of multiple sclerosis (MS).MethodsA total of 114,629 pregnant women were included in the Norwegian Mother, Father and Child Cohort study (1999
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ad992d3e7c6fe62ac179086b503adc
https://hdl.handle.net/11250/2767439
https://hdl.handle.net/11250/2767439
Autor:
Heidi Øyen Flemmen, Cecilia Smith Simonsen, Line Broch, Cathrine Brunborg, Pål Berg-Hansen, Stine Marit Moen, Hege Kersten, Elisabeth Gulowsen Celius
Publikováno v:
Multiple Sclerosis and Related Disorders. 61:103759
Objective: Several studies report an impact of socioeconomic factors on access to disease modifying treatment (DMT) in multiple sclerosis (MS), with a trend of less access to more deprived persons. We investigated the impact of socioeconomic status (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad031bab3e493c56c4038f104a96203
https://doi.org/10.1016/j.msard.2022.103759
https://doi.org/10.1016/j.msard.2022.103759
Autor:
Cecilia Smith Simonsen, Stine Marit Moen, Line Broch, Cathrine Brunborg, Heidi Øyen Flemmen, Elisabeth Gulowsen Celius, Pål Berg-Hansen
Publikováno v:
Journal of Neurology
Objectives Over the past few decades, there has been an improvement in the rate of disability progression in multiple sclerosis (MS) patients, and most studies relate this evolvement to the introduction of disease-modifying therapies. However, severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc96b731e9b8471d5c76e15237404bf8
https://pubmed.ncbi.nlm.nih.gov/33090270
https://pubmed.ncbi.nlm.nih.gov/33090270